Chammas & Marcheteau Advises Turenne Santé on €3 Million Seed Financing of Ventuno Biotech

"Chammas & Marcheteau advised Turenne Santé in the €3 million seed financing of Ventuno Biotech. The round includes a €2 million equity investment led by Octalfa alongside Relyens Innovation Santé, with participation from business angels. Proceeds will advance Ventuno's discovery and translational immuno-oncology programmes."

Chammas & Marcheteau advised Turenne Santé in the €3 million seed financing of Ventuno Biotech. The seed round totals €3 million and comprises a €2 million equity investment led by Octalfa, alongside Relyens Innovation Santé (which was advised by Turenne Santé), with participation from business angels. Founded in early 2025, Ventuno Biotech is a French biotechnology company developing innovative immunotherapies designed to stimulate the antitumour immune response for the treatment of cancers resistant to current therapies. The financing will enable Ventuno Biotech to strengthen its discovery and translational research programmes in immuno-oncology and to advance its portfolio of first-in-class immunotherapies to the next stages of development. Chammas & Marcheteau represented Turenne Santé with a team composed by: Jérôme Chapron (partner) and Nessrine Berrad (associate) on corporate matters; Aude Spinasse (partner) and Constance Parini (associate) on intellectual property; and Coline Bied Charreton (partner) and Emmanuel Corbel (associate) on employment and social law aspects.

Chammas & Marcheteau Advises Turenne Santé on €3 Million Seed Financing of Ventuno Biotech

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads